nach oben

Pituitary

Erschienen in:

01.09.2011

The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas

verfasst von: Lubin Qiu, Dongsheng He, Xiang Fan, Zhi Li, Chuangxin Liao, Yonghong Zhu, Haijun Wang

Erschienen in: Pituitary | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The IL-17 plays a crucial role in the invasion of tumors. However, the effects of IL-17 on the invasion of human pituitary adenomas are still unknown. The current study is designed to investigate the possible involvement of IL-17 in the invasion of adenomas. By collecting invasive and non-invasive pituitary adenomas, the mRNA and protein levels of IL-17, IL-17R and MMP-9 are investigated. The results obtained from IHC showed that the strong positive rate and the total positive rate of IL-17, IL-17R and MMP-9 expression cells in the non-invasive group were 17.1 and 51.43%, 14.3 and 54.3%, 17.1 and 57.1%, respectively. In contrast, the strong positive rate and the total positive rate of the invasive group were significantly higher than that of the non-invasive group, which were 37.5 and 82.5%, 52.5 and 87.5%, 67.5 and 92.5%, respectively. Meanwhile, the serum IL-17 level in the invasive pituitary adenomas patients was significantly higher than in the non-invasive groups (P < 0.05). Furthermore, the mRNA levels of IL-17, IL-17R and MMP-9 were also higher in the invasive group than in the non-invasive group with statistical differences (P < 0.05), and where the expression levels of IL-17 and IL-17R had positive correlation with that of MMP-9 in the invasive group. These results suggested that IL-17 may promote the invasion of pituitary adenomas.

Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620–2627PubMedCrossRef

Pongcharoen S, Niumsup P, Sanguansermsri D, Supalap K, Butkhamchot P (2006) The effect of interleukin-17 on the proliferation and invasion of JEG-3 human choriocarcinoma cells. Am J Reprod Immunol 55:291–300PubMedCrossRef

Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155–174PubMedCrossRef

Ge D, You Z (2008) Expression of interleukin-17RC protein in normal human tissues. Int Archi Med 1:19CrossRef

Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurg Oct 33(4):610–617 discussion 617618CrossRef

Cottier J-P, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469PubMed

Vieira JO Jr, Cukiert A, Liberman B (2006) Evaluation of magnetic resonance imaging criteria for cavernous sinus invasion in patients with pituitary adenomas: logistic regression analysis and correlation with surgical findings. Surg Neurol 65:130–135PubMedCrossRef

Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P (2004) Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol 61:436–446PubMedCrossRef

Nakashiro K, Hayashi Y, Oyasu R (2003) Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10:1149–1153PubMed

10.

Xie L-Q, Bian L-J, Li Z (2010) Co-elevated expression of hepatocyte growth factor and interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep 23:141–150PubMedCrossRef

11.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef

12.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRef

13.

O’Sullivan C, Lewis CE, Harris AL, McGee JO (1993) Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 342:148–149PubMedCrossRef

14.

Pusztai L, Clover LM, Cooper K, Starkey PM, Lewis CE, McGee JO (1994) Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer 70:289–292PubMedCrossRef

15.

Shaoguang W, Rhee K-J, Albesiano E, Rabizadeh S, Xinqun W, Yen H-R, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15(9):1016–1022CrossRef

16.

Kramer JM, Gaffen SL (2007) Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. J Periodontol 78:1083–1093PubMedCrossRef

17.

Xiao M, Wang C, Zhang J, Li Z, Zhao X, Qin Z (2009) IFNγ promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 69(5):2010–2017PubMedCrossRef

18.

Blavier L, Lazaryev A, Dorey F, Shackleford GM, DeClerck YA (2006) Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Res 66:2691–2699PubMedCrossRef

19.

Kawamoto H, Uozumi T, Kamamtot K, Arita K, Yano T, Hirohata T (1996) Type IV collagenase activity and cavenous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien) 138:390–395CrossRef

20.

Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GKK, Lopes MBS, Laws ER Jr (2007) Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 170:356–365PubMedCrossRef

21.

Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MBS, Hussaini IM, Laws ER (2008) Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary 11:37–48PubMedCrossRef

22.

Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Strock 29:1020–1030

23.

Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JA (2000) Role of matrix metalloproteinase -9 in pituitary tumor behavior. J Clin Endocorinol Metab 85:2931–2935CrossRef

24.

Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J Immunol 160:3513–3521PubMed

25.

Jovanovic DV, Martel-Pelletier J, Di Battista JA, Mineau F, Jolicoeur FC, Benderdour M, Pelletier JP (2000) Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum 43:1134–1144PubMedCrossRef

26.

Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14(2):155–174PubMedCrossRef

27.

Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK (1995) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3(6):811–821PubMedCrossRef

28.

Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556–567PubMedCrossRef

29.

Spriggs MK (1997) Interleukin-17 and its receptor. J Clin Immunol 17(5):366–369PubMedCrossRef

30.

Ge D, You Z (2008) Expression of interleukin-17RC protein in normal human tissues. Int Archi Medicine 1:19CrossRef

31.

Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR, Schwarzenberger P, van den Berg WB, Lubberts E (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 52:3239–3247PubMedCrossRef

32.

Honorati MC, Cattini L, Facchini A (2007) Possible prognostic role of IL-17R in osteosarcoma. J Cancer Res Clin Oncol 133:1017–1021PubMedCrossRef

33.

Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT (2006) Transforming growth factor-β induces development of the T_H17 lineage. Nature 441:231–234PubMedCrossRef

34.

Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Immunol 27:485–517CrossRef

35.

Numasaki M, Lotze MT, Sasaki H (2004) Interleukin-17 augments tumor necrosis factor-a-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 93:39–43PubMedCrossRef

36.

Takahashi H, Numasaki M, Lotze MT, Sasaki H (2005) Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 98:189–193PubMedCrossRef

37.

Honorati MC, Neri S, Cattini L, Facchini A (2006) Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthr Cartil 14:345–352PubMedCrossRef

38.

Heidenreich R, Ro¨ cken M, Ghoreschi K (2009) Angiogenesis drives psoriasis pathogenesis. Int J Exp Path 90:232–248CrossRef

39.

Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183:4169–4175PubMedCrossRef

40.

Zhang B, Rong G, Wie H, Zhang M, Bi J, Ma L, Xue X, Wie G, Liu X, Fang G (2008) The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374:533–537PubMedCrossRef

41.

Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175:6177–6189PubMed

42.

Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59:3698–3704PubMed

43.

Wang L, Tangsheng Y, Kortylewski M, Pardoll DM, Zeng D, Yu HJ (2009) IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. Exp Med 206(7):1457–1464CrossRef

44.

Langowski JL, Zhang X, Wu L (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465PubMedCrossRef

45.

Xiao M, Wang C, Zhang J, Zhiguang L, Zhao X, Qin Z (2009) IFNγ promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 69:2010–2017PubMedCrossRef

46.

Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21:467–476PubMedCrossRef

47.

Zhu X, Mulcahy LA, Mohammed RAA, Lee AHS, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM (2008) IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10:R95PubMedCrossRef

48.

Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung JW, Filler SG, Masso-Welch P, Edgerton M, Gaff en SL (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206(2):299–311PubMedCrossRef

49.

Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357–359PubMedCrossRef

Titel: The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas
verfasst von: Lubin Qiu
Dongsheng He
Xiang Fan
Zhi Li
Chuangxin Liao
Yonghong Zhu
Haijun Wang
Publikationsdatum: 01.09.2011
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 3/2011
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-011-0292-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells

Excess mortality for patients with residual disease following resection of pituitary adenomas

Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis

Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population

Intrapituitary cytokines in Cushing’s disease: do they play a role?

Successful treatment of Cushing’s disease caused by ectopic intracavernous microadenoma

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin